Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122336) titled 'Efficacy and Safety of Iparomlimab and Tuvonralimab (QL1706) plus Docetaxel in patients with advanced lung squamous cell carcinoma resistant to prior PD-1/PD-L1 inhibitor therapy: A Phase ? Trial' on April 13.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Condition:
Lung squamous cell carcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-04-13
Target Sample Size: Treatment Group (Single-arm):30;
Countries of Recruitment:
China
To k...